First- and Second-Generation Antipsychotics for Children and Young Adults
Clinical Questions Addressed by the Comparative Effectiveness Review (1 of 2)
The literature reviewed for the comparative effectiveness review was limited to studies performed in children, adolescents, and young adults from 1 to 24 years of age.
Key Questions addressed by the review included:
What is the comparative efficacy or effectiveness of first-generation (FGAs) and second-generation (SGAs) antipsychotics for treating disorder-specific and nonspecific symptoms?
Do FGAs and SGAs differ in short-term (within 6 months) and long-term (after 6 months) outcomes, including:
- Response rate and relationship to dosage; speed of response; duration of response; remission; relapse; time to discontinuation; and adherence
- Growth and maturation; cognitive and emotional development
- Suicidal behaviors and ideation
- Work-related functional capacity; school performance
- Patient insight into illness
- Medication adherence
- Patient- or caregiver-reported outcomes
- Health-related quality of life
- Legal or justice system interactions
- Health care system utilization
- Seida J, Schouten J, Mousavi S, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 11(12)-EHC077-EF. Available at www.effectivehealthcare.ahrq.gov/pedantipsych.cfm.
Your slide tray is being processed.